Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest announcement is out from Carisma Therapeutics ( (CARM) ).
Carisma Therapeutics Inc. announced the voluntary delisting of its common stock from Nasdaq, effective December 10, 2025, following a suspension due to noncompliance with Nasdaq Listing Rules. The company plans to terminate its reporting obligations under the Securities Exchange Act of 1934. Additionally, the company experienced significant leadership changes with the resignation of Natalie McAndrew as Vice President of Finance and the appointment of Steven Kelly as interim CEO and Craig R. Jalbert as CEO starting January 1, 2026, to oversee the company’s wind-down activities.
The most recent analyst rating on (CARM) stock is a Sell with a $0.06 price target. To see the full list of analyst forecasts on Carisma Therapeutics stock, see the CARM Stock Forecast page.
Spark’s Take on CARM Stock
According to Spark, TipRanks’ AI Analyst, CARM is a Underperform.
Carisma Therapeutics’ overall stock score is primarily impacted by its poor financial performance, with significant challenges in profitability, financial stability, and cash flow. The technical analysis shows a bearish trend, and the valuation suggests potential undervaluation but also reflects market concerns. The lack of earnings call and corporate events data limits additional insights.
To see Spark’s full report on CARM stock, click here.
More about Carisma Therapeutics
Average Trading Volume: 1,285,329
Technical Sentiment Signal: Strong Sell
Current Market Cap: $2.03M
For a thorough assessment of CARM stock, go to TipRanks’ Stock Analysis page.